Women's perceptions of and experiences with the use of misoprostol for treatment of incomplete abortion in central Malawi: a mixed methods study.

Pregnancy Female Humans Misoprostol / therapeutic use Abortion, Incomplete / drug therapy Abortifacient Agents, Nonsteroidal / therapeutic use Cross-Sectional Studies Malawi Abortion, Induced / methods Abortion, Spontaneous
First trimester Incomplete abortion Misoprostol Post-abortion care

Journal

Reproductive health
ISSN: 1742-4755
Titre abrégé: Reprod Health
Pays: England
ID NLM: 101224380

Informations de publication

Date de publication:
02 Feb 2023
Historique:
received: 23 05 2022
accepted: 12 12 2022
entrez: 3 2 2023
pubmed: 4 2 2023
medline: 7 2 2023
Statut: epublish

Résumé

Abortion-related complications are among the common causes of maternal mortality in Malawi. Misoprostol is recommended for the treatment of first-trimester incomplete abortions but is seldom used for post-abortion care in Malawi. A descriptive cross-sectional study that used mixed methods was conducted in three hospitals in central Malawi. A survey was done on 400 women and in-depth interviews with 24 women receiving misoprostol for incomplete abortion. Convenience and purposive sampling methods were used and data were analysed using STATA 16.0 for quantitative part and thematic analysis for qualitative part. From the qualitative data, three themes emerged around the following areas: experienced effects, support offered, and women's perceptions. Most women liked misoprostol and reported that the treatment was helpful and effective in expelling retained products of conception. Quantitative data revealed that the majority of participants, 376 (94%) were satisfied with the support received, and 361 (90.3%) believed that misoprostol was better than surgical treatment. The majority of the women 364 (91%) reported they would recommend misoprostol to friends. The use of misoprostol for incomplete abortion in Malawi is acceptable and regarded as helpful and satisfactory among women. One of the major causes of maternal mortality is complications after abortion and miscarriages. The importance of post-abortion care in preventing such deaths justifies the necessity of making treatment accessible and available to every woman in need. Misoprostol is one of the approved treatments for incomplete abortion but is rarely used in developing countries. A study was conducted in three hospitals in central Malawi where women filled in a questionnaire and were interviewed after receiving misoprostol for incomplete abortion. The study's goal was to investigate women’s experiences and feelings about using misoprostol. The findings showed that the majority of the women received medication and counselling as a form of support. They expressed satisfaction with the support and described misoprostol as being useful in removing retained products of conception from the womb. The medication was preferred and regarded as a reliable treatment that was also good for women. The majority of the women reported tolerable side effects of the drug and would recommend it to friends. In conclusion, the use of misoprostol for early incomplete abortion in Malawi is acceptable and is regarded as helpful, and satisfactory to women receiving post-abortion care. The research findings support expanding use of misoprostol in post-abortion care in Malawi.

Sections du résumé

BACKGROUND BACKGROUND
Abortion-related complications are among the common causes of maternal mortality in Malawi. Misoprostol is recommended for the treatment of first-trimester incomplete abortions but is seldom used for post-abortion care in Malawi.
METHODS METHODS
A descriptive cross-sectional study that used mixed methods was conducted in three hospitals in central Malawi. A survey was done on 400 women and in-depth interviews with 24 women receiving misoprostol for incomplete abortion. Convenience and purposive sampling methods were used and data were analysed using STATA 16.0 for quantitative part and thematic analysis for qualitative part.
RESULTS RESULTS
From the qualitative data, three themes emerged around the following areas: experienced effects, support offered, and women's perceptions. Most women liked misoprostol and reported that the treatment was helpful and effective in expelling retained products of conception. Quantitative data revealed that the majority of participants, 376 (94%) were satisfied with the support received, and 361 (90.3%) believed that misoprostol was better than surgical treatment. The majority of the women 364 (91%) reported they would recommend misoprostol to friends.
CONCLUSIONS CONCLUSIONS
The use of misoprostol for incomplete abortion in Malawi is acceptable and regarded as helpful and satisfactory among women.
One of the major causes of maternal mortality is complications after abortion and miscarriages. The importance of post-abortion care in preventing such deaths justifies the necessity of making treatment accessible and available to every woman in need. Misoprostol is one of the approved treatments for incomplete abortion but is rarely used in developing countries. A study was conducted in three hospitals in central Malawi where women filled in a questionnaire and were interviewed after receiving misoprostol for incomplete abortion. The study's goal was to investigate women’s experiences and feelings about using misoprostol. The findings showed that the majority of the women received medication and counselling as a form of support. They expressed satisfaction with the support and described misoprostol as being useful in removing retained products of conception from the womb. The medication was preferred and regarded as a reliable treatment that was also good for women. The majority of the women reported tolerable side effects of the drug and would recommend it to friends. In conclusion, the use of misoprostol for early incomplete abortion in Malawi is acceptable and is regarded as helpful, and satisfactory to women receiving post-abortion care. The research findings support expanding use of misoprostol in post-abortion care in Malawi.

Autres résumés

Type: plain-language-summary (eng)
One of the major causes of maternal mortality is complications after abortion and miscarriages. The importance of post-abortion care in preventing such deaths justifies the necessity of making treatment accessible and available to every woman in need. Misoprostol is one of the approved treatments for incomplete abortion but is rarely used in developing countries. A study was conducted in three hospitals in central Malawi where women filled in a questionnaire and were interviewed after receiving misoprostol for incomplete abortion. The study's goal was to investigate women’s experiences and feelings about using misoprostol. The findings showed that the majority of the women received medication and counselling as a form of support. They expressed satisfaction with the support and described misoprostol as being useful in removing retained products of conception from the womb. The medication was preferred and regarded as a reliable treatment that was also good for women. The majority of the women reported tolerable side effects of the drug and would recommend it to friends. In conclusion, the use of misoprostol for early incomplete abortion in Malawi is acceptable and is regarded as helpful, and satisfactory to women receiving post-abortion care. The research findings support expanding use of misoprostol in post-abortion care in Malawi.

Identifiants

DOI: 10.1186/s12978-022-01549-w PMID: 36732793 PMC: PMC9893686
pubmed: 36732793
doi: 10.1186/s12978-022-01549-w
pii: 10.1186/s12978-022-01549-w
pmc: PMC9893686
doi:

Substances chimiques

Misoprostol 0E43V0BB57
Abortifacient Agents, Nonsteroidal 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

26

Subventions

Organisme : Helse Nord Norway
ID : (2020/39645)

Informations de copyright

© 2023. The Author(s).

Références

Lancet. 2022 Aug 27;400(10353):670-679
pubmed: 36030811
Taiwan J Obstet Gynecol. 2019 Nov;58(6):748-756
pubmed: 31759522
BMC Pregnancy Childbirth. 2020 Mar 29;20(1):184
pubmed: 32223759
Reprod Health Matters. 2015 Feb;22(44 Suppl 1):16-25
pubmed: 25702065
PLoS One. 2014 Jun 25;9(6):e100728
pubmed: 24963882
Sultan Qaboos Univ Med J. 2019 Feb;19(1):e38-e43
pubmed: 31198594
PLoS One. 2019 Jan 10;14(1):e0210449
pubmed: 30629715
Obstet Gynecol. 2018 Apr;131(4):625-631
pubmed: 29528925
Int J Gynaecol Obstet. 2012 Nov;119(2):170-3
pubmed: 22935620
Arch Gynecol Obstet. 2013 Dec;288(6):1243-8
pubmed: 23708389
Med Teach. 2020 Aug;42(8):846-854
pubmed: 32356468
BMC Pregnancy Childbirth. 2012 Nov 14;12:127
pubmed: 23150927
Int J Gynaecol Obstet. 2015 Feb;128(2):160-4
pubmed: 25468057
PLoS One. 2016 Feb 12;11(2):e0149172
pubmed: 26872219
Int J Gynaecol Obstet. 2012 Nov;119(2):166-9
pubmed: 22935621
J Biosoc Sci. 2022 Sep;54(5):760-775
pubmed: 34325755
PLoS One. 2017 Apr 3;12(4):e0173639
pubmed: 28369114
Int J Gynaecol Obstet. 2014 Sep;126(3):223-6
pubmed: 24893962
BMJ Open. 2017 Oct 10;7(10):e016157
pubmed: 29018067
Int J Environ Res Public Health. 2021 Oct 07;18(19):
pubmed: 34639806
J Obstet Gynaecol. 2014 Nov;34(8):726-9
pubmed: 24988526
BMC Health Serv Res. 2015 Dec 17;15:562
pubmed: 26677840
Health Care Women Int. 2020 Jul;41(7):732-760
pubmed: 31855511
Int J Environ Res Public Health. 2018 Feb 21;15(2):
pubmed: 29466308
PLoS One. 2018 Oct 24;13(10):e0205239
pubmed: 30356264
Glob Health Sci Pract. 2019 Aug 27;7(Suppl 2):S299-S314
pubmed: 31455626
Int Perspect Sex Reprod Health. 2013 Jun;39(2):88-96
pubmed: 23895885
Reprod Health. 2019 Feb 19;16(1):20
pubmed: 30782201

Auteurs

Bertha Magreta Chakhame (BM)

Norwegian University of Science and Technology, Trondheim, Norway. bchakhame@kuhes.ac.mw.
Kamuzu University of Health Sciences, Blantyre, Malawi. bchakhame@kuhes.ac.mw.

Elisabeth Darj (E)

Norwegian University of Science and Technology, Trondheim, Norway.

Mphatso Mwapasa (M)

Norwegian University of Science and Technology, Trondheim, Norway.
Kamuzu University of Health Sciences, Blantyre, Malawi.

Ursula Kalimembe Kafulafula (UK)

Kamuzu University of Health Sciences, Blantyre, Malawi.

Alfred Maluwa (A)

Malawi University of Science and Technology, Thyolo, Malawi.

Jon Øyvind Odland (JØ)

Norwegian University of Science and Technology, Trondheim, Norway.
School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, 0002, South Africa.
Faculty of Biosciences and Aquaculture, Nord University, Bodø, Norway.

Maria Lisa Odland (ML)

Norwegian University of Science and Technology, Trondheim, Norway.
Department of Obstetrics and Gynecology, St. Olav's University Hospital, Trondheim, Norway.
Malawi-Liverpool-Welcome Trust Research Institute, Blantyre, 312225, Malawi.
Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, L69 3BX, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Reproduction › Grossesse › Women's perceptions of and experiences with...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Women's perceptions of and experiences with...
questionsmedicales.fr › Facteurs biologiques › Médiateurs de l'inflammation › Prostaglandines synthétiques › Prostaglandines E synthétiques › Misoprostol › Women's perceptions of and experiences with...
questionsmedicales.fr › Maladies urogénitales › Maladies de l'appareil urogénital féminin et complications de la grossesse › Complications de la grossesse › Avortement incomplet › Women's perceptions of and experiences with...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents régulateurs de la reproduction › Abortifs › Abortifs non stéroïdiens › Women's perceptions of and experiences with...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études transversales › Women's perceptions of and experiences with...
questionsmedicales.fr › Régions géographiques › Afrique › Afrique subsaharienne › Afrique australe › Malawi › Women's perceptions of and experiences with...
questionsmedicales.fr › Procédures de chirurgie opératoire › Procédures de chirurgie obstétrique › Avortement provoqué › Women's perceptions of and experiences with...
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Reproduction › Grossesse › Issue de la grossesse › Avortement spontané › Women's perceptions of and experiences with...